VRTX vs CRBU Stock Comparison: AI Score, Valuation, Performance and Upside
Vertex Pharmaceuticals is generally evaluated as an established, profitable biotech with a validated commercial gene-editing therapy alongside its core franchise, while Caribou Biosciences is assessed as a clinical-stage CRISPR cell therapy company entirely dependent on future trial success. The comparison contrasts a proven, cash-generative biotech against a small, pre-revenue genome-editing pure play.
Use this comparison to weigh Vertex's proven commercial execution and financial strength against Caribou Biosciences' early-stage, higher-risk CRISPR cell therapy pipeline.
VRTX holds the edge across 4 of 5 key metrics in this comparison. VRTX leads on both 1-year return (+24.72%) and forward P/E quality (24.63x vs -0.52x for CRBU), a relatively favorable combination of momentum and valuation. VRTX leads on both revenue growth (12.50%) and operating margin (38.05%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for CRBU (+1137.36%) than for VRTX (+3.96%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a profitable, diversified biotech franchise
- Value a company with an already-approved commercial gene-editing therapy
- Prefer lower binary clinical trial risk than early-stage biotechs
- Are comfortable with a premium valuation reflecting franchise quality
- Are comfortable with early-stage clinical and cash-runway risk
- Believe allogeneic, off-the-shelf cell therapies represent the next wave of oncology treatment
- Want small-cap, high-risk exposure to CRISPR genome-editing technology
- Can tolerate potential dilution as the company funds clinical development
| Metric | VRTX | CRBU |
|---|---|---|
| AI scorei | 56.4 | 22.4 |
| AI ranki | #142 | #4009 |
| Latest closei | $508.75 | $0.47 |
| 1M returni | -1.14% | -63.39% |
| 3M returni | +4.67% | -71.99% |
| 6M returni | +16.78% | -78.37% |
| 1Y returni | +24.72% | -83.63% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VRTX | CRBU |
|---|---|---|
| 1Y ago | $12.45K (+24.5%) started 2025-10-16 | $1.64K (-83.6%) started 2025-10-15 |
| 5Y ago | $28.14K (+181.4%) started 2021-10-18 | $223.13 (-97.8%) started 2021-10-15 |
| 10Y ago | $63.2K (+532.0%) started 2016-10-17 | $284.93 (-97.2%) started 2021-07-23 |
Hypothetical — past performance does not guarantee future results.
| Metric | VRTX | CRBU |
|---|---|---|
| Market capi | $137.3B | $49.82M |
| Trailing P/Ei | 31.55 | N/A |
| Forward P/Ei | 24.63 | -0.52 |
| Price/Salesi | 10.42 | 4.96 |
| EV/Revenuei | 10.44 | -3.57 |
| Analyst targeti | $563.12 | $5.75 |
| Target upsidei | +3.96% | +1137.36% |
| Metric | VRTX | CRBU |
|---|---|---|
| Revenue growthi | 12.50% | -43.80% |
| Earnings growthi | 8.00% | N/A |
| EPS growthi | +8.00% | N/A |
| FCF margini | +20.88% | -593.98% |
| Operating margini | 38.05% | -1690.39% |
| Profit margini | 35.00% | 0.00% |
| ROIC proxyi | 23.54% | -78.27% |
| Return on equityi | 23.54% | -78.27% |
| Dividend yieldi | N/A | 0.00% |
| Payout ratioi | 0.00% | N/A |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.30 | 2.31 |
| Debt/equityi | 9.77 | 27.17 |
| Current ratioi | 3.19 | 6.49 |
| Quick ratioi | 2.54 | 6.36 |
Over the past year, VRTX and CRBU have moved weakly in the same direction (correlation of 0.27), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VRTX | CRBU |
|---|---|---|---|
| 1Y | Growthi | +24.51% | -83.63% |
| CAGRi | +24.55% | -83.65% | |
| Volatilityi | 28.78% | 82.46% | |
| Sharpe ratioi | 0.75 | -1.77 | |
| Sortino ratioi | 1.21 | -2.08 | |
| Max drawdowni | 15.21% | 83.80% | |
| Current drawdowni | 8.82% | 83.63% | |
| Avg drawdowni | 6.08% | 37.75% | |
| Ulcer Indexi | 7.63% | 40.04% | |
| Max daily dropi | 4.56% | 45.64% | |
| Max wkly dropi | 9.32% | 62.30% | |
| 5Y | Growthi | +181.39% | -97.77% |
| CAGRi | +23.01% | -53.26% | |
| Volatilityi | 29.07% | 86.72% | |
| Sharpe ratioi | 0.71 | -0.49 | |
| Sortino ratioi | 0.99 | -0.69 | |
| Max drawdowni | 29.07% | 98.02% | |
| Current drawdowni | 8.82% | 98.00% | |
| Avg drawdowni | 7.32% | 78.54% | |
| Ulcer Indexi | 9.61% | 80.74% | |
| Max daily dropi | 20.60% | 45.64% | |
| Max wkly dropi | 20.71% | 62.30% | |
| 10Y | Growthi | +531.99% | -97.15% |
| CAGRi | +20.25% | -49.36% | |
| Volatilityi | 32.61% | 87.76% | |
| Sharpe ratioi | 0.59 | -0.38 | |
| Sortino ratioi | 0.88 | -0.55 | |
| Max drawdowni | 41.60% | 98.48% | |
| Current drawdowni | 8.82% | 98.46% | |
| Avg drawdowni | 10.89% | 80.33% | |
| Ulcer Indexi | 14.64% | 82.90% | |
| Max daily dropi | 20.70% | 45.64% | |
| Max wkly dropi | 22.29% | 62.30% |
| Category | VRTX | CRBU |
|---|---|---|
| Company | Vertex Pharmaceuticals Incorporated | Caribou Biosciences, Inc. |
| Sector | Healthcare | Biotechnology |
| Industry | Biotechnology | Biotechnology |
| Core business | Vertex Pharmaceuticals develops and markets therapies for cystic fibrosis and is expanding into pain management, diabetes, and gene-editing treatments including an approved CRISPR-based therapy. | Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-edited allogeneic cell therapies for cancer and autoimmune diseases. |
| Investor focus | Investors watch cystic fibrosis franchise durability, commercial uptake of its approved gene-editing therapy, and pipeline diversification progress. | Investors track clinical trial progress for its allogeneic CAR-T and CAR-NK cell therapy candidates and the company's cash runway relative to development spending. |
- Dominant, highly profitable franchise in cystic fibrosis treatments
- Approved commercial gene-editing therapy demonstrating platform validation
- Strong balance sheet funding continued pipeline diversification
- Differentiated allogeneic, off-the-shelf cell therapy approach using CRISPR editing
- Pipeline targeting both oncology and autoimmune disease applications
- Proprietary genome-editing technology platform with broad application potential
- Long-term reliance on cystic fibrosis franchise for the bulk of revenue
- New therapy launches carry commercial execution and reimbursement risk
- Complex manufacturing and delivery logistics for cell and gene therapies
- Clinical-stage company with no approved commercial products generating revenue
- Ongoing cash burn requiring careful capital management or future dilution
- Competitive and crowded cell therapy and gene-editing landscape
Compare more than two at a time
This page is a fixed writeup on VRTX and CRBU. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside VRTX and CRBU, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.